Cyclin Dependent Kinase Inhibitor 1B (CDKN1B) Antibody

Product Graph
260€ (50 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Cyclin Dependent Kinase Inhibitor 1B (CDKN1B) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx211680
tested applications
ELISA, WB, IHC

Description

CDKN1B Antibody is a Rabbit Polyclonal against CDKN1B.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Cyclin Dependent Kinase Inhibitor 1B (CDKN1B)
Host
Rabbit
Reactivity
Human, Mouse
Recommended Dilution
ELISA: 1/1000 - 1/2000, WB: 1/200 - 1/1000, IHC: 1/10 - 1/50. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Antigen Affinity Chromatography.
Size 1
50 µl
Size 2
100 µl
Form
Liquid
Tested Applications
ELISA, WB, IHC
Buffer
PBS, pH 7.4, containing 0.05% NaN3 and 40% Glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P46527
Gene ID
1027
Background
Antibody anti-CDKN1B
Status
RUO

Descripción

Related Products

EH4327

Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit

Ver Producto
EM0914

Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit

Ver Producto
FNab06068

CDKN1B antibody

CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.

Ver Producto